click company/industri name report summari
price estim chang
coversin activ bp regulatori path hsct-tma liquid visibl maintain buy pt
flow machin pick steam buy pt
investor focu squar post-aducanumab posit maintain hold
bite appl revolutionprelud possibl acceler trend buy ye target
solid stori unfold buy pt
repres strong start buy pt
runway day articul analyst event rais pt reiter buy
hum along best-in-class fundament buy pt
solid result hold pt
updat model follow recent acquisit osiri new revenu report structur reiter
buy rais price target
expect deliveri guidanc quell demand fear maintain buy pt
hard poke hole anoth solid print guid
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
back index
coversin activ bp regulatori path hsct-
aktx report posit initi data first three bullou pemphigoid bp
patient aktx also report result provid visibl liquid last month
aktx conclud success type pre-ind meet fda regard plan clinic
trial coversin pediatr hematopoiet stem cell transplant-rel thrombot
microangiopathi hsct-tma like becom lead indic manag
continu make solid progress follow departur two ceo
bp updat aktx report data first three bp patient bp
sever auto-immun skin blister diseas patient
accumul suspect caus six-week open-label trial coversin
nine patient primari endpoint bp area index bpdai day
coversin reduc bpdai score addit
encourag clinic biomark data patient also meaning reduct
blister day respect note patient
topic steroid show signific improv bdai blister prior
coversin coversin safe well-toler treatment-rel
high fatal rate unmet need hsct-tma like lead indic
coversin thrombot microangiopathi tma class blood disord
sever complic hematopoiet stem cell transplant hsct reboot
bodi immun system healthi cell hsct approv treat cancer
leukemia multipl myeloma lymphoma autoimmun disord tma result
thrombosi blood clot small blood vessel caus multi-organ damag
associ poor outcom tma affect hsct recipi
fatal rate children hsct-tma orphan indic
complement activ hsct-tma indic poor prognosi hsct-
tma coversin show promis european societi blood marrow
transplant meet septemb dr robert chiesa great ormond street
hospit london uk report data two uk pediatr hsct-tma patient treat
coversin patient show rapid reduct complement activ
normal platelet count red blood cell fragment thrombocytopenia ldh
therapi one patient made complet recoveri die lung damag
caus tma children treat named-pati basi aktx intend
initi registr trial hsct-tma
model updat aktx report unrestrict cash compani book
tax tax credit aktx receiv cash tax credit
drew atm facil aspir capit updat
model includ hsct-tma adjust pnh ahu market model reflect
develop competit landscap
upcom mileston april expect data coversin atop
keratoconjunct akc arvo expect initi potenti
registr us eu pediatr hsct-tma trial
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
flow machin pick steam buy pt
there much pick aspen report annual spend acceler
sixth consecut quarter firm rais guidanc margin top
period aspen return gener quarter sharehold via
buyback furthermor macro commentari sound stabl slightli improv
traction apm includ firm first ever book quarter
support invest enhanc growth bottom line aspen
deliv expect slightli better continu believ busi
cours continu gradual acceler growth next coupl
year term stock said preview upper third
valuat rang wed like buy stock ideal wed trade around
forward rang roughli pe/g increas price target
high end valuat rang give us upsid
softwar sector investor chase growth everyth expens like
idea least portion portfolio high visibl high margin name
that aspen fit improv growth still come bet
continu grind higher buy
highlight print
bullish item aspen increas fiscal year annual spend guidanc high-end
impli growth renew surpris upsid challeng
part busi continu show sign recoveri led improv activ
america aspen hold analyst day conjunct user confer may
provid anoth round favor commentari
bearish item unclear impact acceler invest apm across
go-to-market implement develop may margin past
preced aspen tend invest behind growth dont expect impact
increment spend materi impact profit note margin
dictat swing revenu
differ view commentari apm traction quit upbeat
includ firm first ever book bit surpris aspen
narrow full year growth contribut around midpoint high-end
previou guidanc wed make two observ rais full year annual spend
guidanc keep apm flat good sign rest busi particularli
 continu show sign improv rememb apm still
quit small today high-end guidanc impli busi
even though grow fast rest much larger annual spend pie also
get better hard apm meaning contribut growth
deriv read-through aspen bit one-off within coverag
suppos sign renew activ american broadli bode well firm
like burgeon construct portfolio higher-level aspen margin
profil evid well-execut vertic model look like scale
suggest firm like veeva perhap altair realiz bit
differ continu see healthi oper leverag growth
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
investor focu squar post-
pipelin event come investor clamor busi develop
report adj ep beat estim consensu
solid spinraza sale lower expens main driver
beat vs model quarter solid view focu call
unsurprisingli us see preview might posit better
wake recent aducanumab earli alzheim diseas failur manag
remind investor least mid- late-stag data readout come
end note neuroscience-rel drug develop remain
rel riski endeavor plu side continu like abil gener
robust cash flow exampl solid defens core multipl
sclerosi franchis spinraza spinal muscular atrophi valuat said
believ stock appear need extern late commercial-stage-focus busi
develop activ get post-aducanumab rut activ remain
inher unpredict us outsid maintain
vumer ms gi data import appear lowest-hang fruit readout
continu expect head-to-head gastrointestin gi toler data vumer
diroximel fumar vs tecfidera dimethyl fumar recal tecfidera
multipl sclerosi largest product current sale
rev subject sever gener challeng see anoth inter
part review on-going vumer alreadi file action date
paid mileston last year preliminari gi data see
view upcom gi data rel low-hang fruit vs riski data set
progress supranuclear palsi psp lupu data
mid late-stag catalyst epilepsi parkinson al small-fib neuropathi
cognit impair associ schizophrenia stroke etc expect
end competitor-rel catalyst await us approv novarti
zolgensma formerli per nv pleas see tabl detail
list catalyst
major chang model dcf-base pt remain
make substanti chang revenu estim ep
vs larg due flow beat
ep vs mainli higher oper expens continu
includ specif valu brand pipelin believ could overli
conserv dcf-base price target remain remain construct
evid upsid impli price target also continu
believ difficult us use might larg valuation-bas argument
fight current investor skeptic around stock
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
bite appl revolutionprelud possibl
bottom line would buyer recent pullback
share print soft neg impact multipl recent market
develop paclitaxel mesh men health steril issu think near-
term overhang larg price stock experi
aftershock aforement think tide start turn bsx favor
continu least time frame
project acceler organ revenu growth organ cc
year-end current model y/i growth
think growth could eventu low dd said done becom
easi comp confid support robust litani product catalyst
even includ accret growth expect btg acquisit close btg
grow med-tech franchis watchman flx europ market launch
japan lotu edg launch us/europ sentinel ramp via attach lotu
ramp adopt two compel technolog uroph augmenix nxthera
recent code latter import notwithstand top-lin miss
still showcas solid oper leverag ex-one-tim think revenu
growth acceler could exacerb leverag drive ep beyond street un-
guid estim inde late june analyst meet could offer indic
sum would buy stock ahead sever near-term event hr meet early-
may watchman ep applic digest diseas week updat mid-may dispos
scope-applic europcr late-may lotu acur watchman sentinel applic
close btg acquisit firm biennial analyst day late june
bullish thesi stock continu predic firm long-term growth
prospect top- bottom-lin think exceed peer ensu
updat outlook manag anticip total sale growth
report basi vs previous includ approxim impact
recent acquisit nxthera claret augmenix btg contribut
current includ guidanc manag provid updat guidanc
follow deal closur current anticip adjust ep expect
rang high end firm prior guidanc rang
guidanc manag anticip total report sale growth
rang organ revenu growth expect rang exclud
approxim expect contribut recent acquisit nxthera
claret augmenix current rate fx expect headwind
adjust ep anticip rang y/i
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
solid stori unfold buy pt
facebook report solid result stabl user trend ex-fx advertis
revenu growth stronger profit exclud ftc accrual expens
manag continu expect revenu growth deceler year relat
on-going mix shift stori ad load price lower compar core
facebook newsfe ad ad target relat headwind includ third parti
platform well initi roll-out function would allow user
clear brows histori facebook measur proactiv address
privaci framework global countri adopt gdpr-like regul
meantim compani lower oper expens outlook ex-ftc accrual
stori engag monet appear progress nice advertis
engag format last quarter improv stori monet
could lead upsid estim next coupl quarter continu like
long-term growth outlook rais price target
user metric stabl stori aid engag facebook mau dau grew
leav engag daus/mau roughli unchang asia
row remain main driver dau expans respect
india indonesia philippin lead dau matur market us
canada europ remain near engag appear pick across
facebook entir famili app dau increas
mau approxim stori format becom increasingli popular
million user view stori across facebook instagram
advertis out-performance continu though growth expect moder
advertis revenu increas y/i ex-fx vs beat
consensu us canada strongest perform region
continu robust arpu growth manag expect ad revenu growth continu
deceler sequenti remaind impact headwind
relat ad-target well continu mix shift stori ad
current less expens ad format lower stori monet
impact revenu growth near-term attract roi spur strong advertis
uptak meantim checkout instagram function gain traction
beta today brand
guidanc impli modest upward revis full-year profit ex-ftc accrual
guidanc call continu deceler revenu growth year
amid ad-target suppli transit stori headwind broadli consist
outlook offer januari total expens growth ex-ftc accrual expect
year vs prior target though management note
impli chang outlook invest product infrastructur safeti
secur impact oper margin capital-expenditure also modestli adjust
primarili alloc spend data center
estim chang valuat rais price target
base adj ebitda estim pt support dcf valuat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
aerospac defens
repres strong start buy pt
report strong ep compar estim
consensu organ growth quarter gross
margin compar estim believ ep
beat stronger anticip increment margin manag
sound confid full year outlook even uncertainti
maintain buy rate push price target expect
plan investor day may anoth catalyst stock compani
updat medium-term like guidanc
surpris much discuss confer call focus
impact manag indic seen chang
plan deliveri continu believ total
content associ engin nacel continu
run behind schedul thu less like see slowdown materi pull
estim total risk earn assum rate
like stay push shift
lead time less program manag
indic see slowdown pull would abl reposit
capac commerci program help confid potenti
continu provid strength indic
rate manag confid
continu drive growth across continu model growth
commerci aerospac busi ahead full year hsd guidanc
commerci aerospac segment current assum rate hold steadi
compani maintain full-year financi guidanc like broad-
base strength quarter believ strong execut contribut higher
confid full year outlook believ lack increas guidanc
reflect uncertainti fact one quarter
maintain ep estim respect
manag made point reiter revenu ep cadenc
even similar still reflect slight increas
ep expect follow typic season strength
believ estim conserv current assum
increment margin full year could low manag indic
see reason increment margin sustain sound like
manag resum buy-back activ gotten leverag
gross basi like defens portfolio appear well posit hit
double-digit growth base strength arc acquisit price
target base blend ep multipl ebitda multipl appli
estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
lifestyl brand retail
runway day articul analyst event rais pt
reiter buy
unveil impress plan investor day larg consist
expect outlook call low-teen revenu compound-annual-growth-rate next five year
vs mid-teen estimate coupl modest annual gross margin expans
sg leverag in-lin expect drive oper incom growth
excess revenu growth combin coupl share buyback expect
result ep growth in-lin ahead oper incom growth annual base
assumpt estim earn power approxim
impli compound-annual-growth-rate line expect importantli
plan incorpor materi increment revenu certain new categori
like footwear self care could prove sourc upsid plan
footwear believ take slow method approach categori
entri ensur uniqu point view offer prefer given inher
complex differ skill set need make work given nascenc
idea long develop cycl like see brand footwear
store least two year believ final take comfort commentari
team made around momentum busi last year continu
bode well ep rais comp
vs previous take everyth togeth continu view
vast growth opportun ahead squar sight reiter
buy rate rais pt
three driver behind strategi also consist preview growth strategi
base three key driver category/product innov focus core
categori women bottom also expand core outerwear omni
experi store experi digit expect doubl membership
intern expect quadrupl led asia china particular importantli
growth balanc across geographi na ldd intern categori
women ldd men compound-annual-growth-rate channel store ldd e-commerc
overal believ opportun expand address market go
run train immens ampli fuel sale earn growth
product innov drive categori innov highli encourag
momentum wit product innov scienc feel philosophi
pave way brand build success core categori like
women bottom introduc jogger wide leg also strengthen categori
like bra expand high-support categori articul particular focu
expand beyond yoga especi run train categori align
core custom sweatlif fabric innov also play key role expand
product offer end compani launch new fabric sens knit
overal believ strong innov pipelin result strong
also enabl compani achiev long term target
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
hum along best-in-class fundament buy
pt
bullet-proof strong combin day manag non-
deal roadshow plu quarter result plu independ field work lead us
conclud like becom third cloud softwar firm reach
billion market cap within year mean implicitli believ stock price
doubl sooner basi assert get
forward ev/fcf multipl valuat seem
quit reason given firm grow least
realiz buy rate consensu make wrong
confid reiter buy rate
quarter guid differ theme releas big success
feder govern excit sell-sid caller obvious happi
success howev around long realiz govern
contract extrem difficult forecast inde becam target
firm experienc multipl whiff mostli caus govern
spend variabl point nobodi expect govern contract
come linearli caveat acknowledg juggernaut realli
struggl find meaning kink firm armor especi compani
chip away low end self-built applic
read-through ignor suggest
materi neg impact workday atlassian salesforc workday
compani make organ softwar work better think
firm busi replac nich legaci applic delusion
suggest becom domin system record firm
broadli bad day market share loss segment bmc
broadcom/ca nearli certain continu sever year come
highlight quarter
bullish item normal subscript bill growth strong
margin solidli ahead consensu number custom acv
end feder custom
acv emerg product platform add-on continu make larger
portion new acv core account mix year ago
renew rate solid om quarter
bearish item record hire quarter bulk reflect
expens led june quarter oper margin guid slightli
forecast though like conservat manag reiter margin
year flat year ago firm invest drive growth
implicitli assum inflect next year firm reach target call
margin wed note firm path easili blow
revenu target presum leeway margin given faster growth
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
solid result hold pt
paypal report solid result within guidanc essenti in-lin
consensu past year consensu non-gaap ep estim paypal
increas stock dramat
multipl expans seem driven combin stock market
strength along financials-ori investor look stock
attract growth altern financi stock would surpris see
multipl expans continu suspect stock need see upward estim
revis work go forward
lead y/i growth second quarter row tpv grew y/i fx-neutral
third straight quarter help merchant servic tpv growth
mobil tpv growth mobil tpv revenu grew y/i deceler
gener top paypal volum funnel perform well
volum continu act headwind marketplac tpv declin
y/i continu steadi downward trajectori growth year ago
overal tpv appear pois declin go forward continu
becom smaller mix paypal better-perform area help tpv
growth stay high rest
venmo remain major bright spot venmo tpv grew deceler
modestli growth billion venmo revenu run rate grew
assum million venmo revenu
take rate implic billion around venmo
tpv monet marqui merchant like seamless hulu
fandango venmo revenu still somewhat immateri less
overal paypal stay trajectori becom meaning next
partnership continu expand instagram checkout announc last month
still earli vast potenti paypal invest mercadolibr come
board observ right lead oper partnership
acceler paypal growth latin america cross-bord volum
mix guidanc revenu guidanc billion
modestli prior estim non-gaap ep guidanc
also estim howev manag reiter revenu outlook
call growth billion rais ep rang
account benefit
meli invest dilut acquisit
make minor estim chang increas price target
base non-gaap ep estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
updat model follow recent acquisit osiri
price target
happen april smith nephew announc complet two
recent acquisit healthcar addit late
snn releas updat histor revenu breakdown align
oper structur new ceo put place adjust model
new report structur well closur recent acquisit
thought stock overal continu think snn comprehens
view differenti product portfolio support market share gain
pick momentum renew focu execut
new leadership implement ceo ultim drive margin expans
current forecast view recent acquisit posit provid core
us orthoped wound care busi differenti higher-growth asset
also provid snn flexibl addit deal next month
net net think snn share offer attract risk/reward investor current
level consensu ep think investor take advantag
transit period leadership begin build posit ahead think
prolong period execut market share gain support new ceo/
manag team comprehens differenti product portfolio
updat recent acquisit recal call snn manag made
point focu increas activ specif snn note goal increas
corpor leverag lt rang willing go rang
long deal includ reason timelin back lt rang specul
immedi turn larger deal like link note would
immedi occupi capac snn quickli execut sever smaller
tuck-in acquisit exist core market name osiri healthcar
osiri provid snn portfolio fast-grow differenti regen
medicin asset across wound care orthoped busi unit snn
acquir osiri repres revenu osiri focus
regen medicin product includ skin substitut bone substitut
cartilag replac wound care orthoped sport medicin market
grafix cryopreserv placent membran skin substitut treatment
acut chronic wound repres revenu growth
osiri snn note dd revenu growth expect continu move forward
technolog complement exist us wound care franchis
channel product perspect look addit commentari
trade call may
financi impact osir expect modestli contribut revenu
neutral earn accret earn addit
leverag beyond updat revenu estim includ
contribut annual note conserv model
revenu dis-synergi year primarili result osir pre-exist
distribut agreement major snn competitor arthrex
cartiform repres osir revenu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
expect deliveri guidanc quell
demand fear maintain buy pt
post result roughli expect yet real stori
solid deliveri guidanc vehicl help abat
specif quarter compani report revenu ep
comparison expect
compani end quarter cash comment cash
level expect rise subsequ quarter year
updat model s/x electron capabl kw charg
reduc charg time along motor upgrad extend rang
help spur demand vehicl
one interest develop compani state month
plan offer insur product consum given tradit
insur tend expens brand await detail view
anyth lower consum cost ownership clear benefit demand
lot move part quarter given initi push
eu china tone manag appear balanc
maintain buy rate new price target base upon new
ep estim
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
aerospac defens
report core ep compar estim
focu result confer call impact
ground result broadli better expect compani
provid bracket eventu impact howev compani also
suspend guidanc surpris believ result
present complet pictur impact period cost on-go
perspect maintain hold rate price target
indic initi estim put cost issu
current aircraft block reflect larg higher overhead
associ extend deliveri schedul estim repres
hit margin total bca margin next year
howev expect substanti step-up period cost associ
ground although compani reflect much softwar
train cost period expens would note higher cost
includ potenti airlin compens cost alreadi
contempl initi cash impact ground less investor
fear clearli larger risk plenti liquid howev
ultim impact yet determin depend length ground
believ uncertainti remain overhang stock
compani suspend guidanc surpris
believ uncertainti time ground ba desir get
front regulatori process virtual necess ba take stand
time lift ground howev compani sound confid
time potenti lift complet flight new mca
softwar highlight oper use new system
simul manag took conciliatori tone call well
receiv appreci get final regulatori approv regulatori agenc
besid faa ultim determin time return servic
perform bd gener strong top-lin growth
margin margin benefit bp gain real estat sale
segment book new order backlog continu see
full year bd margin believ ba benefit
maintain hold rate price target believ full
impact ground yet reflect stock current
model fairli aggress ramp return servic still see
risk around time ground compani abil recov
miss deliveri macro backdrop continu
surpris upsid see increment risk backlog airlin jet
airway garuda lion norwegian use ground re-work order deliveri
schedul price target base blend ep multipl
ebitda multipl appli estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
hard poke hole anoth solid print guid
anoth boringli excel quarter realli struggl poke hole microsoft
quarter guid fact firm growth continu meaning better
hope would transpir upgrad stock degre deris
back novemb thesi back growth segment busi
azur upgrad broaden xbox game half revenu
grow pace remain sale legaci extent
subject convers cloud offer good transit classic legaci
server much smaller telecom effort
surprisingli shini object growth driver legaci compon
firm oper grew faster even upsid hope surprisingli
legaci busi doesnt decay fast expect aggreg growth
busi exce expect estim go led stock higher
see reason conclud trend chang anytim next quarter
tend under-perform sharpli upward tape seen far
follow hedg fund panic stock market bear market november-decemb
opinion overal market low valu believ like
scenario sedat overal advanc bode well probabl
outperform deliv alpha investor custom reiter
buy rate
quarter guid differ commerci book growth strong
weve seen sinc renew recaptur lag custom boost
figur on-premis growth good larg longer date contract show
book punchlin green light across board quarter
guid drill segment best thing azur growth
better expect y-i constant-curr margin
leverag good job optim hardwar final
alway hesit use over-us phrase inflect point believ hybrid
comput actual mainstream smack middl favor
move stream upgrad expans new logo win certainli support
observ
read-through hybrid well comment could implicit posit
firm like buy ceridian hold
 buy mix model solut
custom
price target revisit model revis forthcom model updat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
